AI Consensus Investment Thesis
Tarsus Pharmaceuticals (TARS) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
No Action - Keep Monitoring
Only one horizon is positive; wait for broader confirmation.
1-Year
NEUTRAL$81
+16.4%5-Year
BUY$156
+124.0%Latest flagship insight
Why This High Margin Biotech Monopoly Is Nearing An Earnings Inflection Point
A sharp divergence exists regarding this asset's regulatory compliance, contrasting its explosive commercial launch and software-tier gross margins with alleged copay subsidy risks. While consensus supports the underlying therapeutic monopoly and imminent cash-flow inflection, potential federal scrutiny on patient assistance programs remains the primary downside risk.
This is the latest published deep-analysis batch. Audit previous forecasts in full transparency
Warren Buffett (Value Purist), Superintelligence (Anthropologist), Ray Dalio (Strategist), Machiavelli (Insider), Elon Musk (Visionary), Michael Burry (Vulture), J.P. Morgan (Titan), Sherlock Holmes (Whistleblower). Some archetypes run in multiple modes, resulting in 12 advisors total.
Research support only. We don't give financial advice.
Gemini
Claude
ChatGPT
GrokExecutive Summary
Dotted terms open concise definitions. Browse technical terms
Interactive forecast chart
The core investment thesis centers on a rapid phase transitionphase transitionPhase transition describes a nonlinear shift in system behavior when gradual changes cross a threshold and produce a new state.View full glossary entry from a cash-consuming commercial launch to a highly profitable, self-funding therapeutic monopoly. With gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry sustained at an elite ninety-three percent, the asset exhibits immense operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry as revenue scales against a stabilizing fixed-cost base. While the macroeconomic regimemacroeconomic regimeThe prevailing set of economic conditions including interest rates and inflation that influence asset pricing.View full glossary entry of elevated interest rates compresses growth multiplesgrowth multipleGrowth multiple is a valuation premium assigned to businesses expected to sustain faster expansion than peers or the broader market.View full glossary entry, this asset's inelastic demandinelastic demandDemand that changes proportionally less than price over a defined range and period.View full glossary entry and imminent free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry generation provide robust structural insulation. However, a sharp divergence exists regarding the legal durability of its patient-compliance and copay-subsidy frameworks, which could trigger regulatory frictionregulatory frictionCost, delay, or uncertainty created by regulatory approval, compliance, supervision, or changing rules.View full glossary entry.
Key insights
- Elite ninety-three percent gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry provide software-tier unit economicsunit economicsRevenue, variable cost, contribution profit, and acquisition or retention economics measured for one customer, product, transaction, or operating unit.View full glossary entry and absolute pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry in an inflationary environment.
- Imminent transition to positive GAAP net income and free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry eliminates near-term dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry and refinancing risks entirely.
- Pipeline expansion utilizing the same de-risked active pharmaceutical ingredient offers highly efficient, non-linear total addressable markettotal addressable marketTotal addressable market (TAM) is the full revenue opportunity available if a product or service achieved complete adoption within its relevant market.View full glossary entry expansion.
- Single-asset concentration and single-source contract manufacturing represent critical operational vulnerabilities that require permanent risk discounting.
- Regulatory scrutiny regarding patient assistance programs and federal pricing caps could compress net realized price per prescription.
- The asset remains a highly attractive, de-risked acquisition target for larger pharmaceutical incumbents facing imminent patent cliffs.
- Quantitative re-rating is expected as the company transitions into profitable growth screens within the next twelve months.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Forecasts—and what could close the gap?
Market Narrative
What does the market currently expect? The conventional market narrative views the company as a highly successful but vulnerable single-product commercial launch story. While the sell-side applauds the rapid adoption and impressive revenue growth of its primary eye-care drug, a persistent fear remains that script growth will soon plateau and that single-asset risk is too high. Additionally, the crowd is heavily distracted by recent short-seller allegations regarding patient assistance programs and potential regulatory violations. Consequently, the market anchors its valuation to standard, speculative biotech multiples, treating the asset as a niche specialty pharma play rather than a highly profitable, category-defining monopoly.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The core information gap lies in the market's mechanical misclassification of the company's financial lifecycle and platform potential. The crowd prices the asset as a speculative, cash-burning biotech vulnerable to high interest rates. However, forensic analysis reveals a business with ninety-three percent gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry on the immediate precipice of sustained free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry generation. The market fails to appreciate the immense operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry of this transition, which will soon render the company entirely self-funding. Furthermore, the crowd discounts the pipeline as a speculative call option, missing the thermodynamic efficiencythermodynamic efficiencyThe ratio of useful output to total energy input in a physical process or system.View full glossary entry of reusing a biologically de-risked molecule across massive adjacent indications like Lyme disease. This transition from capital consumer to cash compoundercash compounderA business that generates high returns on invested capital and reinvests cash to grow value over time.View full glossary entry is highly undervalued.
Repricing Catalyst
What could make the market recognize and close that gap? The primary convergence catalyst is the formal reporting of the company's first quarter of positive GAAP net income and sustained positive free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry, expected within the next two to three quarters. Crossing this mathematical threshold will permanently dismantle the speculative cash-burner narrative, forcing quantitative screeners and institutional growth funds to aggressively accumulate the stock. A secondary catalyst is the upcoming clinical trial data readouts for adjacent indications, which will validate the platform's expansion and shatter the single-product constraint.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Mixed
- Volatility
- Mixed
- Cycle position
- Growing Awareness
Sentiment is highly bifurcated. While institutional momentum and growing awareness of the company's rapid commercial scaling drive optimistic sentiment, a parallel fear regime exists due to short-seller allegations and regulatory scrutiny. This creates a sharp split between investors focused on fundamental cash-flow inflection and those fearing regulatory intervention.
Macro Regime Fit
Does the current market environment support the thesis? The macro regimemacro regimeA persistent combination of growth, inflation, policy, and liquidity conditions affecting asset prices.View full glossary entry alignment is mixed but structurally constructive. While the Federal Reserve's tighter-for-longer interest rate policy and elevated term premia act as severe headwinds for speculative, cash-burning biotechnology peers, they function as a relative tailwind for this asset. Because the company is on the verge of self-funding profitability with a fortress balance sheetfortress balance sheetA financial position with high liquidity and low debt, providing resilience against market volatility.View full glossary entry, it is insulated from high borrowing costs and dilutive capital markets. Furthermore, its ninety-three percent gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry and inelastic healthcare demand provide an exceptional hedge against stagflationarystagflationAn economic condition characterized by stagnant growth, high unemployment, and high inflation.View full glossary entry input-cost pressures.
Advisor Disagreement
What do our AI Advisors disagree about most? The primary disagreement across the reports stems from divergent risk weightings regarding regulatory compliance and the sustainability of the commercial model. One faction assumes a highly bearish outlook, heavily weighting the risk of a Department of Justice investigation into patient copay assistance programs, which they believe could collapse Medicare volumes. Conversely, the bullish consensus views these concerns as transient short-seller noise, prioritizing the rapid S-curve adoption of the drug and imminent free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry generation. There is also minor disagreement regarding the addressable marketaddressable marketAddressable market is the portion of the broader market that a business can realistically target with its offering, geography, and distribution.View full glossary entry size, with some modeling rapid saturation while others project long-term expansion.
Base-Case Forces
Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| XDEMVY Commercial Hyper-Scaling | Innovation And Product | +45% | +120% | The rapid commercial adoption of XDEMVY as the first and only FDA-approved treatment for Demodex blepharitis is driving explosive top-line growth. With over ninety percent commercial payer coverage and deep physician penetration, the drug is capturing a massive, previously untreated patient population. This inelastic biological demand ensures highly predictable, compounding revenue that is insulated from broader macroeconomic cycles and will persist over the long-term patent runway. |
| Operating Leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry and Profitability Inflection | Operational Efficiency | +30% | +100% | The company is approaching a major phase transitionphase transitionPhase transition describes a nonlinear shift in system behavior when gradual changes cross a threshold and produce a new state.View full glossary entry as its elite ninety-three percent gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry collide with a stabilizing fixed SG&A cost base. Operating losses have collapsed rapidly, putting the company on the immediate precipice of sustained GAAP profitabilitygaap profitabilityGAAP profitability refers to earnings that remain positive under generally accepted accounting principles, including standard operating and noncash expense recognition.View full glossary entry and positive free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry. This self-funding capability eliminates dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry risk and will force a systematic re-rating of the asset. |
| Platform-in-a-Product R&D Strategy | Innovation And Product | +25% | +30% | By leveraging its core active ingredient, lotilaner, across adjacent indications like ocular rosacea and Lyme disease prophylaxis, the company operates a highly efficient R&D engine. This strategy recycles a biologically de-risked molecule, significantly reducing clinical failure risks and capital intensitycapital intensityA business condition where large upfront spending on assets and infrastructure is needed to operate and grow.View full glossary entry while opening massive new total addressable markets. |
| Fortress Balance Sheetfortress balance sheetA financial position with high liquidity and low debt, providing resilience against market volatility.View full glossary entry and Capital Independence | Macroeconomic And Macrofinancial | +15% | +10% | With a current ratio of 3.85, minimal debt, and substantial cash reserves, the company possesses absolute financial sovereignty. This capital independence shields the asset from the restrictive high-rate monetary environment and credit market shocks, allowing management to fund clinical trials and commercial expansion without dilutive financing. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Regulatory Scrutiny of Copay Assistance | Regulatory | -30% | -40% | Allegations regarding the legality of the company's patient copay assistance programs represent a significant regulatory frictionregulatory frictionCost, delay, or uncertainty created by regulatory approval, compliance, supervision, or changing rules.View full glossary entry. If federal authorities investigate these circular funding mechanisms under the Anti-Kickback Statute, the company could face severe fines, forced restructuring of its subsidy programs, and a subsequent collapse in Medicare script volume. |
| Single-Asset Concentration Vulnerability | Competitive Positioning | -20% | -15% | The company's valuation is heavily concentrated on a single molecule and product. Any localized disruption, such as post-marketing safety signals, manufacturing bottlenecks, or competitive generic workarounds, represents a single point of failure that would disproportionately impair the company's intrinsic valueintrinsic valueThe estimated true worth of a business or asset based on fundamentals instead of short-term market mood.View full glossary entry and cap its valuation multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry. |
| Pharmacy Benefit Manager Rebate Pressures | Regulatory | -15% | -20% | As prescription volumes scale, Pharmacy Benefit Managers are likely to demand increasingly aggressive rebates to maintain favorable formulary placement. This gross-to-net discount pressure acts as a structural ceiling on net realized price per bottle, potentially compressing operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry and slowing the trajectory toward peak profitability. |
| BIOSECURE Supply Chainsupply chainThe network of suppliers, producers, logistics providers, distributors, and customers involved in creating and delivering a product or service.View full glossary entry Disruption | Regulatory | -10% | -15% | Geopolitical decouplinggeopolitical decouplingA reduction in trade, investment, technology exchange, or supply-chain integration between countries or geopolitical blocs.View full glossary entry and legislative mandates like the BIOSECURE Actbiosecure actBiosecure Act refers to legislation aimed at limiting reliance on certain biotechnology suppliers or data-linked firms for national security reasons.View full glossary entry introduce friction into the company's contract manufacturing relationships. If forced to migrate active pharmaceutical ingredient sourcing away from Chinese partners to Western facilities, the company faces transition costs, regulatory delays, and potential margin compressionmargin compressionThe narrowing of profit margins due to rising costs or declining pricing power.View full glossary entry. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| DOJ Subpoena and Copay Program Halt | 25% | -55% | Regulatory | The Department of Justice issues a formal subpoena investigating the company's relationship with patient assistance charities. This forces an immediate halt to the copay subsidy program, causing Medicare script volumes to collapse overnight and triggering massive legal fines that drain the company's cash reserves. |
| Post-Market Corneal Toxicity Signal | 10% | -70% | Innovation And Product | As the primary drug scales to hundreds of thousands of real-world patients, a rare but severe delayed-onset adverse event, such as corneal toxicity, is identified. This triggers a black box warning or outright market withdrawal, instantly vaporizing the commercial thesis for the monoline company. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Lyme Disease Prophylaxis Clinical Success | 35% | +55% | Innovation And Product | The upcoming Phase 2 readout for TP-05 demonstrates near-perfect efficacy in preventing Lyme disease post-tick bite with a clean safety profile. This breakthrough creates a massive, entirely unpriced public health market, transforming the company from a niche eye-care player into a broad infectious disease platform. |
| Strategic Big Pharma Acquisition | 30% | +45% | Capital Allocation | A cash-rich pharmaceutical giant facing imminent patent cliffs launches a hostile or friendly buyout of the company to secure its high-margin, de-risked commercial asset. This acquisition would instantly bypass multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry and realize the terminal valueterminal valueThe present value of all future cash flows beyond the explicit forecast period.View full glossary entry of the XDEMVY franchise at a massive premium. |
Company Financial Analysis
Tarsus Pharmaceuticals Earnings and Financials Analysis by AI
Financial figures available as of Jul 05, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
The company is showing incredible financial growth, with sales skyrocketing by over one hundred and forty percent year-over-year to reach a run rate of over five hundred million dollars. Most financial reviews agree that the company is on the very edge of turning a real profit, as its massive sales growth is quickly shrinking its historical losses. However, there is a clear clash on whether this growth is sustainable. Optimistic views suggest that the business will become a self-funding cash machine within the next year, completely protecting it from high interest rates. On the other hand, cautious perspectives warn that if the company is forced to change how it helps patients pay for its drug, sales could suddenly slow down, leaving the company with high overhead costs and delayed profits.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 451.4M | USD -66.4M | USD -22.3M |
| 2024 | USD 183M | USD -115.6M | USD -84.6M |
| 2023 | USD 17.4M | USD -135.9M | USD -123M |
| 2022 | USD 25.8M | USD -62.1M | USD -49.5M |
| 2021 | USD 57M | USD -13.8M | USD 3.2M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | -- | TTM | Loss-making | USD / USD |
| 2024 | -- | TTM | Loss-making | USD / USD |
| 2023 | -- | TTM | Loss-making | USD / USD |
| 2022 | -- | Annual | Loss-making | USD / USD |
| 2021 | -- | Annual | Loss-making | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
The company boasts an elite ninety-three percent gross profit margin, which is exceptionally rare and comparable to high-margin software companies. This reflects the absolute pricing power of its patented eye-care monopoly. While operating margins are currently negative due to high launch and marketing costs, they are improving rapidly and heading toward positive territory. There is high consensus that operating margins will eventually reach a highly profitable thirty to forty percent range. However, a major disagreement exists regarding the durability of these margins. Cautious outlooks warn that aggressive negotiations from insurance middlemen and potential government price caps could force the company to offer steep discounts, dragging margins down. Optimists argue that the company's monopoly power will easily shield its margins from these pricing pressures.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD -71M | -15.7% | -14.7% |
| 2024 | USD -120.6M | -65.9% | -63.2% |
| 2023 | USD -143.2M | -820.5% | -778.9% |
| 2022 | USD -62.7M | -242.9% | -240.5% |
| 2021 | USD -12.2M | -21.3% | -24.2% |
Balance sheet and leverage
The company's balance sheet is widely considered a financial fortress, offering excellent safety for investors. With nearly four hundred million dollars in cash and virtually no debt, the company has a very high current ratio of nearly four, meaning it has plenty of short-term liquidity. All reviews agree that this strong position completely insulates the company from high interest rates and tight credit markets, as it does not need to borrow money or dilute shareholders to fund its operations. However, there is a key disagreement regarding potential hidden risks. Cautious analysts warn that a major government investigation could lead to massive fines that would quickly drain this cash pile, while optimistic analysts believe the cash is entirely safe and provides great flexibility to fund new clinical trials.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 93.6M | USD 417.3M | USD 90M net cash | 3.85x |
| 2024 | USD 72.5M | USD 291.4M | USD 22.4M net cash | 4.42x |
| 2023 | USD 30.2M | USD 227.4M | USD 194.7M net cash | 6.93x |
| 2022 | USD 20.2M | USD 217M | USD 51.5M net cash | 14.61x |
| 2021 | USD 1.9M | USD 171.8M | USD 169.4M net cash | 15.33x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
The company operates an incredibly "asset-light" business model, meaning it does not need to spend heavy capital on building factories or buying expensive equipment. Physical capital spending is extremely low, hovering at around two percent of its total sales. Instead, the company focuses its spending on marketing to drive drug adoption and on research to expand its pipeline. There is strong agreement that this low investment intensity is a massive advantage, as it allows almost all gross profits to turn directly into free cash flow once sales scale up. The main point of disagreement is whether the heavy marketing and patient subsidy spending is a permanent, expensive necessity to maintain sales, or if this spending will naturally flatten out and allow profit margins to expand as the product becomes the standard of care.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 9.9M | USD 64.3M |
| 2024 | USD 1.6M | USD 53.4M |
| 2023 | USD 5.5M | USD 50.3M |
| 2022 | USD 506K | USD 42.6M |
| 2021 | USD 586K | USD 41.7M |
Quarterly Forecast Scenarios
Tarsus Pharmaceuticals Quarterly Forecast Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Timeline | Bear Case Stock Price (USD) | Base Case Stock Price (USD) | Bull Case Stock Price (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $55.62 | $68.22 | $75.26 | $736.09 | |
| $44.50 | $71.41 | $82.78 | $724.14 | |
| $37.82 | $75.07 | $92.72 | $713.57 | |
| $34.04 | $80.90 | $109.40 | $723.38 | |
| $30.64 | $85.16 | $118.16 | $716.61 | |
| $28.19 | $89.71 | $129.97 | $738.34 | |
| $26.78 | $92.55 | $136.47 | $746.91 | |
| $24.10 | $96.03 | $146.02 | $771.93 | |
| $22.89 | $96.84 | $142.99 | $782.73 | |
| $22.89 | $103.15 | $154.43 | $807.31 | |
| $24.04 | $109.27 | $164.80 | $822.72 | |
| $25.24 | $113.96 | $184.58 | $846.10 | |
| $25.24 | $117.04 | $193.81 | $852.53 | |
| $26.50 | $121.92 | $209.31 | $882.91 | |
| $26.50 | $128.94 | $221.87 | $900.46 | |
| $27.83 | $136.17 | $244.06 | $922.67 | |
| $28.39 | $140.53 | $253.82 | $935.91 | |
| $28.39 | $144.32 | $269.05 | $952.30 | |
| $29.80 | $149.94 | $282.50 | $976.28 | |
| $30.40 | $155.75 | $302.28 | $1,002 |
Research Provenance
References & Context
This Tarsus Pharmaceuticals consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 12
- AI Researchers
- 7
- AI Thinkers
- 5
Sources retained from AI Researcher searches
Showing the top 2 of 2 deduplicated sources retained for this batch.
Some model providers retained only the consulted domain, not an exact article URL. Those domains are shown as evidence without inventing a link.
- 01stocktitan.netstocktitan.net
- 02tarsusrx.comtarsusrx.com
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
- File size
- 90.8K bytes
- Words
- 12.8K words
- Characters
- 90.8K characters
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market Context through 2026-05-31
Download Archived SnapshotCoverage 2026-01-01 to 2026-05-31 · Knowledge cutoff 2026-05-31
- File size
- 78K bytes
- Words
- 10.9K words
- Characters
- 78K characters
This year-to-date package described the geopolitical, macroeconomic, monetary-policy, technology, trade, energy, and cross-asset developments available through the batch knowledge cutoff of 2026-05-31.
It supplied dated market and policy context, including rates, sovereign yields, equities, foreign exchange, energy, metals, and digital assets, for the forecast generation workflow.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| The Iran and Strait of Hormuz conflict shocked energy markets | 2026-02-28 | STARTED AND ONGOING |
| U.S. monetary policy entered the Warsh transition | 2026-01-30 | STARTED AND ACTIVE POLICY TRANSITION |
| Agentic AI and infrastructure spending kept expanding | 2026-01-01 | OPEN ENDED |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
34 fieldscostOfRevenue · currency_symbol · date · depreciationAndAmortization · +30 more fields
Balance sheet
64 fieldsaccountsPayable · accumulatedAmortization · accumulatedDepreciation · accumulatedOtherComprehensiveIncome · +60 more fields
Cash flow
32 fieldsbeginPeriodCashFlow · capitalExpenditures · cashAndCashEquivalentsChanges · cashFlowsOtherOperating · +28 more fields
Outstanding shares
4 fieldsdate · dateFormatted · shares · sharesMln
annual: 2020-12-31–2026-01-01, 12 periods; quarterly: 2023-06-30–2026-03-31, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).